^
Association details:
Evidence:
Evidence Level:
Sensitive: A1 - Approval
Published date:
09/19/2018
Excerpt:
Encorafenib is indicated:...in combination with binimetinib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.
Evidence Level:
Sensitive: A2 - Guideline
New
Source:
Excerpt:
Table 3. ESMO-MCBS table for new therapies/indications in melanoma...Adult patients with unresectable or metastatic melanoma with the BRAF V600 mutation.
Evidence Level:
Sensitive: A2 - Guideline
New
Source:
Excerpt:
...Other regimens (for patients with BRAF V600-activating mutation) with the following agents Dabrafenib/trametinib...vemurafenib/cobimetinib...Encorafenib/Binimetinib...
Evidence Level:
Sensitive: B - Late Trials
Title:

602P - COLUMBUS 7-year update: A randomized, open-label, phase III trial of encorafenib (Enco) + binimetinib (Bini) vs vemurafenib (Vemu) or Enco in patients (Pts) with BRAF V600-mutant melanoma

Published date:
11/27/2023
Excerpt:
With a median duration of follow-up of 100 mo, the 7-year analysis from COLUMBUS part 1 confirms the long-term, sustained efficacy and known safety profile of enco + bini, with no new safety signals emerging, in pts with BRAF V600–mutant metastatic melanoma.
Trial ID:
Evidence Level:
Sensitive: B - Late Trials
Source:
Title:

1113P - COLUMBUS 7-year update: A randomized, open-label, phase III trial of encorafenib (enco) + binimetinib (bini) vs vemurafenib (vemu) or enco in patients (pts) with BRAF V600–mutant melanoma

Published date:
10/16/2023
Excerpt:
With a median duration of follow-up of 100 mo, the 7-year analysis from COLUMBUS part 1 confirms the long-term, sustained efficacy and known safety profile of enco + bini, with no new safety signals emerging, in pts with BRAF V600–mutant metastatic melanoma.
Evidence Level:
Sensitive: B - Late Trials
Title:

COLUMBUS 5-year update: a randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF

Published date:
06/13/2023
Excerpt:
Overall, this 5-year update confirmed that people with BRAF V600-mutant melanoma that has spread to other parts of the body and who took encorafenib plus binimetinib were alive for longer without their disease getting worse than those who took vemurafenib or encorafenib alone.
DOI:
10.2217/fon-2022-12
Trial ID:
Evidence Level:
Sensitive: B - Late Trials
Title:

COLUMBUS 5-Year Update: A Randomized, Open-Label, Phase III Trial of Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafenib in Patients With BRAF V600-Mutant Melanoma

Published date:
07/21/2022
Excerpt:
The median duration of response with encorafenib plus binimetinib was 18.6 months, with disease control achieved in 92.2% of patients….In this 5-year update of part 1 of the COLUMBUS trial, encorafenib plus binimetinib treatment demonstrated continued long-term benefits and a consistent safety profile in patients with BRAF V600-mutant melanoma.
DOI:
10.1200/JCO.21.02659
Trial ID:
Evidence Level:
Sensitive: B - Late Trials
Source:
Title:

1041MO - 5-year update on COLUMBUS: A randomized phase III trial of encorafenib (enco) + binimetinib (bini) versus enco or vemurafenib (vem) in patients (pts) with BRAF V600-mutant melanoma

Published date:
09/13/2021
Excerpt:
In COLUMBUS Part 1, 577 pts with advanced/metastatic BRAF V600 melanoma...randomized 1:1:1 to enco 450 mg once daily + bini 45 mg twice daily, enco 300 mg once daily, or vem 960 mg twice daily...In the enco + bini arm, the 5-year OS rate (95% CI) in all pts (n=192)...
Trial ID:
Evidence Level:
Sensitive: B - Late Trials
Source:
Title:

Five-year overall survival (OS) in COLUMBUS: A randomized phase 3 trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients (pts) with BRAF V600-mutant melanoma.

Published date:
05/19/2021
Excerpt:
Part 1 of COLUMBUS, 577 pts with advanced/metastatic BRAF V600-mutant melanoma, untreated or progressed after first-line immunotherapy, were randomized 1:1:1 to encorafenib 450 mg QD + binimetinib 45 mg BID (COMBO450)...For COMBO450, ENCO300, and VEM, the 5-year PFS rate was 22.9%, 19.3%, and 10.2%; ORR (95% CI) was 64.1% (56.8–70.8), 51.5% (44.3–58.8), and 40.8% (33.8–48.2); and the median duration of response (DOR) was 18.6, 15.5, and 12.3 mo, respectively.
DOI:
10.1200/JCO.2021.39.15_suppl.9507
Trial ID:
Evidence Level:
Sensitive: B - Late Trials
Source:
Title:

Update on overall survival in COLUMBUS: A randomized phase III trial of encorafenib (ENCO) plus binimetinib (BINI) versus vemurafenib (VEM) or ENCO in patients with BRAF V600-mutant melanoma.

Published date:
05/13/2020
Excerpt:
Updated median PFS was COMBO450, 14.9 mo (95% CI, 11.0–20.2), ENCO300, 9.6 mo (95% CI, 7.4–14.8), and VEM, 7.3 mo (95% CI, 5.6–7.9). PFS was longer for COMBO450 vs VEM (HR, 0.52 [95% CI, 0.40–0.67])….In the COLUMBUS trial, results for updated PFS and OS with COMBO450 continue to demonstrate long-term benefits in patients with BRAF V600‒mutated melanoma.
DOI:
10.1200/JCO.2020.38.15_suppl.10012
Trial ID:
Evidence Level:
Sensitive: B - Late Trials
New
Title:

Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial

Excerpt:
The combination of encorafenib plus binimetinib provided clinically meaningful efficacy with good tolerability as shown by improvements in both progression-free survival and overall survival compared with vemurafenib.
DOI:
10.1016/S1470-2045(18)30497-2
Evidence Level:
Sensitive: C2 – Inclusion Criteria
New
Title:

A study comparing combination of Encorafenib + Binimetinib as a standard-dose and a High-dose Regimen in patients with BRAFV600-Mutant Melanoma Brain Metastasis

Excerpt:
...Presence of BRAFV600 mutation in tumor tissue previously determined by a local PCR or NGS-based assay at any time prior to Screening or by a central laboratory during Screening.5. ...
Evidence Level:
Sensitive: C2 – Inclusion Criteria
New
Title:

Phase 2 Study of Encorafenib and Binimetinib Plus Pembrolizumab inParticipants With BRAF V600E/K Mutation-Positive Melanoma Who Progressed Duringor After Prior Treatment with Anti−PD-1 Therapy

Excerpt:
...Participants must meet the following key inclusion criteria to be eligible for enrollment into the study:- Male or female participants ≥18 years of age at the time of informed consent.- Histologically confirmed unresectable (Stage IIIB, IIIC, or IIID) or metastatic(Stage IV) cutaneous melanoma, according to the AJCC 8th edition.- Documented evidence of a BRAF V600E or V600K mutation.- Submission of adequate tumor tissue for central laboratory testing of BRAF V600E/K mutation and biomarkers is required for all participants during the screening period and prior to randomization.- Must have received only 1 prior line of systemic therapy for melanoma (either adjuvant therapy or first-line anti-PD-1 monotherapy (ie, nivolumab orpembrolizumab).- Must have anti-PD-1 resistant disease (primary or secondary) with confirmed diseaseprogression per RECIST v1.1 either during or after receipt of an approved anti-PD-1monotherapy (ie, nivolumab or pembrolizumab) for melanoma, defined according tothe SITC Immunotherapy Resistance Taskforce (Kluger et al, 2020).- Have at least 1 measurable lesion per RECIST v1.1.- ECOG PS of 0-1, and adequate organ and cardiac function, including LVEF ≥50%by cardiac imaging.`...
More C2 evidence
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

1114P - Encorafenib (E) plus binimetinib (B) in unresectable advanced or metastatic BRAFV600-mut melanoma, real-world evidence in Spain (GEM 2002 - BECARE)

Published date:
10/16/2023
Excerpt:
BECARE is a retrospective study of EB in unresectable advanced/metastatic BRAFV600-mut melanoma in 21 sites from Spain….The median PFS and OS for pts with brain metastasis treated with EB in the 1st line was 6.3 m (95% CI: 6.2-12) and 10 m (95% CI: 7.4-NR), respectively.
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

837P - Real-world evidence of encorafenib (E) plus binimetinib (B) in unresectable advanced or metastatic BRAFV600-mut melanoma in Spain (GEM 2002 - BECARE)

Published date:
09/05/2022
Excerpt:
BECARE is a retrospective, non-interventional study that investigates real-world effectiveness and tolerability of encorafenib plus binimetinib in unresectable advanced / metastatic BRAFV600-mut melanoma...The ORR to EB was 80.4%. With a median follow up of 13 m (range: 1.1-26.7), median PFS was 11.4 m (95% CI: 9.9-21.6) and 6.6 m (95% CI: 4.4-NR) for pts in first-line and after ICI, respectively. The 12-m OS rate was 72.3% (95% CI: 60.1-87) and 30% (95% CI: 11.6-77.3) for pts in first-line and after ICI, respectively.
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

A phase 2 clinical trial on trametinib and low-dose dabrafenib in advanced pretreated BRAFV600/NRASQ61R/K/L wild-type melanoma (TraMel-WT): Interim efficacy and safety results.

Published date:
05/19/2021
Excerpt:
This two-stage, single-center phase 2 trial investigated T 2 mg QD in patients (pts) with advanced BRAFV600/NRASQ61R/K/L wt melanoma...LD-D (50 mg BID) was added to T (pre-amend)....The ORR in 14 evaluable pts is 42.9% (5 confirmed and 1 unconfirmed partial response), the disease control rate is 71.4%.
DOI:
10.1200/JCO.2021.39.15_suppl.9529
Trial ID:
Evidence Level:
Sensitive: C3 – Early Trials
Title:

Safety and efficacy evaluation of encorafenib plus binimetinib for the treatment of advanced BRAF-mutant melanoma patients

Published date:
08/28/2020
Excerpt:
Consistent survival improvements for encorafenib and binimetinib in BRAF V600 mutated melanoma have been confirmed in clinical trials, with over 4 years of median follow up.
DOI:
10.1080/14740338.2020.1817376
Evidence Level:
Sensitive: C4 – Case Studies
Title:

BRAF/MEK Inhibition as a Bridge to Immunotherapy for Symptomatic BRAF V600 Melanoma Brain Metastases: A Case Series

Published date:
08/29/2023
Excerpt:
A 50-year-old woman with history of left chest wall stage IA (T1aNx) and left leg stage IB (T1bN0) melanoma...Biopsy of a lung lesion confirmed metastatic BRAF V600 melanoma. She was treated with steroids, tapered over 6 weeks, and whole-brain radiation therapy (WBRT) before transitioning to bridging targeted therapy with encorafenib and binimetinib (Table 1). Restaging scans after 6 weeks demonstrated significant treatment response...
DOI:
https://doi.org/10.6004/jnccn.2023.7032